Benitec Biopharma Inc
F:BJ9
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Benitec Biopharma Inc
F:BJ9
|
US |
|
HAL Trust
F:HA4
|
MC |
|
V
|
Vallourec SA
PAR:VK
|
FR |
Benitec Biopharma Inc
Benitec Biopharma Inc. is a biotechnology company that develops genetic medicines designed to silence harmful genes. Its main approach is called DNA-directed RNA interference, a technique that uses a delivered gene to keep a target gene from making the protein that drives disease. The company’s work is aimed at serious inherited and other disorders where turning off a specific gene could change the course of the illness. Benitec does not sell consumer products. It develops drug candidates and licenses or partners around its technology, while aiming to bring its own therapies through clinical testing and, eventually, regulatory approval. Its main customers are not patients directly at this stage, but rather healthcare systems and, potentially, specialty drug buyers if its treatments are approved. The company makes money through research and development funding, partnerships, and future product sales or licensing if its medicines reach the market. What sets Benitec apart is that it is focused on gene silencing at the DNA level rather than the more familiar pill or antibody drug model. That makes it a toolmaker in the gene therapy field, with value tied to a platform that can be aimed at diseases caused by a known genetic target. For beginner investors, the key idea is that Benitec is trying to turn a precise genetic mechanism into a medicine, which puts it in the high-risk, high-science part of biotech.
Benitec Biopharma Inc. is a biotechnology company that develops genetic medicines designed to silence harmful genes. Its main approach is called DNA-directed RNA interference, a technique that uses a delivered gene to keep a target gene from making the protein that drives disease. The company’s work is aimed at serious inherited and other disorders where turning off a specific gene could change the course of the illness.
Benitec does not sell consumer products. It develops drug candidates and licenses or partners around its technology, while aiming to bring its own therapies through clinical testing and, eventually, regulatory approval. Its main customers are not patients directly at this stage, but rather healthcare systems and, potentially, specialty drug buyers if its treatments are approved. The company makes money through research and development funding, partnerships, and future product sales or licensing if its medicines reach the market.
What sets Benitec apart is that it is focused on gene silencing at the DNA level rather than the more familiar pill or antibody drug model. That makes it a toolmaker in the gene therapy field, with value tied to a platform that can be aimed at diseases caused by a known genetic target. For beginner investors, the key idea is that Benitec is trying to turn a precise genetic mechanism into a medicine, which puts it in the high-risk, high-science part of biotech.
Program Progress: Benitec advanced its oncology and OPMD gene therapy programs, with a Phase 2 oncology study now active and OPMD clinical entry targeted for early 2019.
Capital Raised: The company raised $8.8 million through an entitlement offer and placement, with strong support from major shareholders.
Financials: Benitec reported a net loss of $8.6 million for Q3 2018, wider than the $3.1 million loss in Q3 2017, mainly due to reduced R&D grant income.
Cash Position: Cash on hand at the end of March 2018 was $10.5 million, down $6.8 million from June 2017.
Regulatory Momentum: Positive feedback from regulators in key countries supports the clinical advancement of BB-301 for OPMD.
Manufacturing Advances: Significant progress in scalable manufacturing for gene therapy products, with clinical-grade material production ramping up.
